We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Viruses Modified to Combat Harmful ‘Biofilms”

By Biotechdaily staff writers
Posted on 26 Jul 2007
In one of the first potential applications of synthetic biology, an emerging field that aims to design and build useful biomolecular systems, researchers are engineering viruses to attack and destroy the surface "biofilms” that harbor harmful bacteria in the body and on industrial and medical devices.

The researchers, from Massachusetts Institute of Technology (MIT: Cambridge, MA, USA) and Boston University (BU; Boston, MA, USA), have already successfully demonstrated one such virus, and due to a "plug and play” library of "parts,” believe that many more could be custom-designed to target different species or strains of bacteria.

The study, reported in the July 3, 2007 issue of the journal Proceedings of the [U.S.] National Academy of Sciences, helps push synthetic biology from a conceptual science
to one that has proven practical applications. More...
"Our results show we can do simple things with synthetic biology that have potentially useful results,” stated first author Dr. Timothy Lu, a doctoral student in the Harvard University (Cambridge, MA, USA)-MIT Division of Health Sciences and Technology.

Bacterial biofilms can form nearly anywhere, even on teeth if they are not brushed for a day or two. When they accumulate in hard-to-reach areas such as the insides of food processing machines or medical catheters, however, they become persistent sources of infection.

These bacteria excrete a variety of proteins, polysaccharides, and nucleic acids that combined with other accumulating materials form an extracellular matrix, or in Dr. Lu's words, a "slimy layer,” that encloses the bacteria. Conventional remedies such as antibiotics are not as effective on these bacterial biofilms as they are on free-floating bacteria. In some instances, antibiotics even encourage bacterial biofilms to form.

Dr. Lu and senior author Dr. James Collins, professor of biomedical engineering at BU, aim to eradicate these biofilms using bacteriophage, tiny viruses that attack bacteria. Phages have long been used in Eastern Europe and Russia to treat infection.

For a phage to be effective against a biofilm, it must both attack the strain of bacteria in the film and degrade the film itself. Recently, a different group of researchers discovered several phages in sewage that meet both criteria because, among other things, they carry enzymes capable of degrading a biofilm's extracellular matrix.

This finding led the researchers to try modfying phages to carry enzymes with similar capabilities. The reason for this is that finding a good naturally occurring combination for a given industrial or medical problem is difficult. In addition, "people don't want to dig through sewage to find these phages,” noted Dr. Lu.

Therefore, Drs. Collins and Lu defined a modular system that allows engineers to devise phages to target specific biofilms. As a proof of concept, they used their strategy to modify T7, an Escherichia coli-specific phage, to express dispersin B (DspB), an enzyme known to disperse a variety of biofilms.

To evaluate the engineered T7 phage, the team cultivated E. coli biofilms on plastic pegs. The investigators discovered that their engineered phage eliminated 99.997% of the bacterial biofilm cells, an improvement by two orders of magnitude over the phage's nonengineered cousin.

The team's modular approach can be thought of as a "plug and play” library, according to Dr. Collins. "The library could contain different phages that target different species or strains of bacteria, each constructed using related design principles to express different enzymes.” Creating such a library may soon be possible with new technologies for synthesizing genes quickly and inexpensively. "We hope in a few years, it will be easy to create libraries of phage that we know have a good chance of working a priori because we know so much about their inner workings,” said Dr. Lu.

Synthetic biology also makes it possible to control the timing of when a gene is expressed in an organism. For instance, Dr. Lu inserted the DspB genes into a precise location in the T7 genome so that the phage would strongly express it during infection rather than before or after. Such control was possible because T7 was very well characterized by other researchers, such as MIT synthetic biologist Dr. Drew Endy, an assistant professor of biological engineering.

Although phages are not approved for use in humans in the United States, recently the U.S. Food and Drug Administration (FDA) approved a phage cocktail to treat Listeria monocytogenes on lunchmeat. This makes certain applications, such as cleaning products that include phages to eradicate slime in food-processing plants, more immediately promising. Another potential application: phage-containing drugs for use in livestock in exchange for or in combination with antibiotics.


Related Links:
Massachusetts Institute of Technology
Boston University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.